Table I.

Clinical characteristics of 19 patients with Wegener’s granulomatosis

Patient No.Age (Yr)/SexActive Disease ManifestationsaPrior Disease ManifestationsImmunosuppressive TreatmentbcANCA Titer
124/ME, L, S, AE, L, S, K, AAZA, prednisone1:40
231/ME, KE, L, S, KCYC, prednisone1:320
330/ME, LE, L, KCYC1:640
464/FE, L, AE, LNone1:320
555/FE, L, A, MNME, LNone1:160
656/FE, K, AE, K, ANonePositivec
744/FE, L, AE, L, KNonePositivec
821/FE, L, AE, L, ACYC, prednisone1:80
957/ML, AE, L, AMTX1:320
1035/MEY, K, AE, L, KAZA1:80
1133/ML, KE, L, KCYC, prednisone1:640
1241/ME, KE, L, KNone1:160
1324/MRemissionL, K, EYMTX, prednisoneNegative
1454/MRemissionL, K, EY, ANone1:80
1543/MRemissionE, L, K, EYMTX, prednisone1:80
1645/MRemissionL, K, EY, AMTXNegative
1719/MRemissionE, LMTXNegative
1828/FRemissionE, LMTX1:20
1941/MRemissionE, L, K, EYMTX1:160
  • a Disease manifestations at time of in vitro studies: E, upper respiratory tract; L, lung; S, skin; K, kidney; A, rheumatic symptoms; MNM, mononeuritis multiplex; EY, inflammatory eye disease.

  • b Immunosuppressive treatment at time of in vitro studies: AZA, azathioprine; CYC, cyclophosphamide; MTX, methotrexate.

  • c cANCA, titer not done.